8-K filing — Fulcrum Therapeutics, Inc. (FULC)
Filed: 2026-11-12 AccNo: 0001193125-26-458387 Size: 150 KB Item 8.01: Other Events
Stocks · News reference
Fulcrum Therapeutics and Slate Medicines merge in an all-stock deal to develop migraine drugs, backed by a $245M private placement.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-11-12 AccNo: 0001193125-26-458387 Size: 150 KB Item 8.01: Other Events
Fulcrum Therapeutics is anticipated to report a loss of 14 cents per share in its upcoming earnings release.
Law firm Brodsky & Smith announced investigations into four major merger transactions, examining whether company boards breached fiduciary duties by failing to conduct fair processes and ensure fair value for shareholders. The investigations involve Centerspace's acquisition by Independence Realty Trust, Fulcrum Therapeutics' acquisition by Slate Medicines, Weave Communications' acquisition by Francisco Partners, and Personalis' acquisition by Tempus AI.
Combined company to operate as Slate Medicines and focus on advancing Slate's portfolio of next-generation migraine therapeuticsSlate’s lead product candidate, SLTE-1009, is a clinical stage, potentially